CEO
“Our second quarter welcomed two important additions to our team of professionals, Director of Quality Assurance and Regulatory Affairs,
We are now present in a total of 16 countries, including and adding
Another important event that took place in the second quarter of 2022 was our participation in the
As 2cureX grows and becomes even more globally oriented, and in an effort to optimize our resources, we have decided to stop producing our quarterly reports in two languages. We are confident that we are keeping our duty of transparency to our shareholders if, starting from the third quarter of 2022, quarterly reports will only be provided in English.
FINANCIAL HIGHLIGHTS
The financial development is in line with our plans and expectations, and with a cash position of
First half of 2022 (2022-01-01 until 2022-06-30) – the group
Net turnover for the period was 8 KSEK (0 KSEK).
Other operating income was 900 KSEK (4 319 KSEK)
The result before tax was -14 300 KSEK (-8 810 KSEK)
The result per share* was -
The solidity** was 95 % (94 %).
The cash and bank were 55 583 KSEK (78 913 KSEK).
*Earnings per share: Profit for the period divided by the average number of shares. Average number of shares in the first half of 2022: 17 558 642 shares. Total number of shares in
**Equity ratio: Shareholder’s equity divided by total capital.
Significant events during the second quarter 2022
April:
Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program.
Notice of annual general meeting of
May:
2cureX publishes the annual report for the fiscal year 2021.
Redeye research interview with 2cureX CEO,
2cureX appoints
2cureX presents IndiTreat® clinical results at the
IGNITE update: Eight hospitals have been enrolled in the program.
Presenting Dr.
Three IndiTreat® posters were accepted at ESMO-GI 2022
2cureX announces new distributer in
June:
2cureX expands distribution of IndiTreat® to
Significant events after the period
July:
Dr.
Notice of extra general meeting in
August:
Announcement from 2cureX extra general meeting approving warrant package for board member Dr.
© Modular Finance, source